The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
NCT ID: NCT00673075
Last Updated: 2010-09-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
39 participants
INTERVENTIONAL
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Encapsulated Nebivolol
Nebivolol
Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
2
Encapsulated Carvedilol
Carvedilol
Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nebivolol
Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
Carvedilol
Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Coronary artery disease as defined by: status post myocardial infarction (heart attack) greater than 14 days post event with no upper time limit (and followed by stress testing with additional imaging (echocardiographic or nuclear) within the 12 months prior to enrollment) and/or angiographic evidence of one or more major coronary arteries narrowing of greater than 50% and/or a history of percutaneous or surgical coronary revascularization greater than 4 months after that procedure at the time of enrollment.
* Qualifying blood pressure criteria for study entry and for randomization
* Willing to adhere to exercise stress (treadmill) tests
Exclusion Criteria
* Potential coronary surgical/intervention within the next 6 months
* Have any form of secondary hypertension
* Have a history of hypersensitivity to nebivolol, metoprolol, carvedilol, or any beta blocker
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Forest Research Institute, a subsidiary of Forest Laboratories Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tatjana Lukic, MD., M.Sc
Role: STUDY_DIRECTOR
Forest Research Institute, Inc., a Subsidiary of Forest Laboratories, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Peoria, Arizona, United States
Forest Investigative Site
Buena Park, California, United States
Forest Investigative Site
Los Angeles, California, United States
Forest Investigative Site
Orange, California, United States
Forest Investigator Site
Santa Ana, California, United States
Forest Investigative Site
Guilford, Connecticut, United States
Forest Investigator Site
Coral Gables, Florida, United States
Forest Investigative Site
Daytona Beach, Florida, United States
Forest Investigator Site
Hollywood, Florida, United States
Forest Investigator Site
New Smyrna Beach, Florida, United States
Forest Investigative Site
Orlando, Florida, United States
Forest Investigator Site
Winter Haven, Florida, United States
Forest Investigative Site
Chicago, Illinois, United States
Forest Investigator Site
Indianapolis, Indiana, United States
Forest Investigator Site
Lafayette, Louisiana, United States
Forest Investigator Site
Auburn, Maine, United States
Forest Investigative Site
Pittsfield, Massachusetts, United States
Forest Investigator Site
Worcester, Massachusetts, United States
Forest Investigative Site
Detroit, Michigan, United States
Forest Investigative Site
Lansing, Michigan, United States
Forest Investigator Site
Las Vegas, Nevada, United States
Forest Investigative Site
Northport, New York, United States
Forest Investigative Site
The Bronx, New York, United States
Forest Investigative Site
The Bronx, New York, United States
Forest Investigative Site
Charlotte, North Carolina, United States
Forest Investigator Site
Lenoir, North Carolina, United States
Forest Investigative Site
Fargo, North Dakota, United States
Forest Investigative Site
Cincinnati, Ohio, United States
Forest Investigative Site
Lancaster, Pennsylvania, United States
Forest Investigative Site
Charleston, South Carolina, United States
Forest Investigator Site
Florence, South Carolina, United States
Forest Investigative Site
Cleveland, Tennessee, United States
Forest Investigative Site
Carrollton, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEB-MD-06
Identifier Type: -
Identifier Source: org_study_id